RxDoctor Payments Data

Amy Russell

Family · Richmond, VANPI 1184396640

Payments from drug & device makers

$1,432in general payments, 2019–2025

Across 35 payments — averaging $40.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$243
  • Apellis Pharmaceuticals, Inc.$221
  • Ardelyx, Inc.$199
  • Amgen$142
  • Takeda Pharmaceuticals U.S.A., Inc.$107
  • Novartis$98
  • plus $423 from 9 others

What the payments were for

  • Food & beverage$1,432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,432 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$35,272
Medicare patients
214
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin168$146,840
Cinacalcet Hcl190$65,492
JanuviaSitagliptin Phosphate61$55,747
FarxigaDapagliflozin Propanediol39$30,698
LokelmaSodium Zirconium Cyclosilicate31$27,430
Envarsus XrTacrolimus23$21,866
RybelsusSemaglutide19$16,504
TrulicityDulaglutide16$14,388
Tacrolimus127$12,708
Mycophenolic AcidMycophenolate Sodium62$11,948
Methenamine Hippurate150$9,510
EliquisApixaban12$8,017
TradjentaLinagliptin12$6,995
VascepaIcosapent Ethyl16$6,803
Mycophenolate Mofetil96$5,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$20$58,12870 claims
MerckJanuvia$243$55,74761 claims
Novo NordiskRybelsus$87$16,50419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.

Other family in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →